Yes, bisoprolol is cardioselective, and it is one of the most beta-1 selective beta-blockers available. It preferentially targets the receptors on heart muscle cells while largely leaving the receptors in your lungs, blood vessels, and other tissues alone. This selectivity is what makes it a preferred choice for people who need a beta-blocker but have concerns about respiratory or metabolic side effects.
What Cardioselective Actually Means
Your body has two main types of beta-adrenergic receptors. Beta-1 receptors sit primarily on heart cells, where they control heart rate and the force of each contraction. Beta-2 receptors are found in the airways, blood vessels, and liver, where they help relax smooth muscle and regulate blood sugar. A cardioselective beta-blocker preferentially blocks beta-1 receptors, slowing the heart without interfering much with lung function or metabolism.
Bisoprolol’s selectivity comes from how it physically interacts with these two receptor types. Research published in Pharmacology Research & Perspectives found that bisoprolol dissociates from beta-1 receptors 50 times more slowly than from beta-2 receptors. It essentially lingers on heart receptors while releasing quickly from receptors elsewhere. The same study described bisoprolol as “the only truly beta-1 selective compound based on its kinetic affinity” among the clinically used beta-blockers tested.
How It Compares to Other Beta-Blockers
Not all cardioselective beta-blockers are equally selective. Using the non-selective drug propranolol as a baseline of 1, bisoprolol has a relative beta-1 selectivity of about 12, compared to roughly 9 for metoprolol and 6 for acebutolol. Atenolol, often called cardioselective, still blocks about 25% of beta-2 receptors at its higher recommended doses.
This difference shows up in clinical testing. In a head-to-head study of people with COPD, bisoprolol at its maximum dose (20 mg) did not increase airway resistance at either 4 or 24 hours after dosing. Atenolol at its maximum dose (100 mg) increased airway resistance at both time points. Bisoprolol also maintained its heart-rate-lowering effect for a full 24 hours, while atenolol’s cardiac effect wore off sooner. In other words, bisoprolol kept working on the heart longer and bothered the lungs less.
A separate study in healthy volunteers confirmed the pattern: bisoprolol at 20 mg did not interfere with blood vessel relaxation (a beta-2 function), while atenolol at 100 mg did.
Selectivity Has Limits at High Doses
Cardioselectivity is relative, not absolute. At high doses, all selective beta-blockers begin to block beta-2 receptors as well. This is especially relevant in overdose situations, where bisoprolol can cause respiratory symptoms that wouldn’t normally appear at standard doses. At the doses typically prescribed (2.5 to 10 mg daily), bisoprolol maintains strong selectivity for the heart.
Why Selectivity Matters for Your Lungs
Beta-2 receptors in the airways help keep the bronchial tubes open. Blocking them can trigger airway tightening, which is a real concern for people with asthma or COPD. Because bisoprolol largely spares beta-2 receptors, it has a better safety profile for these patients than non-selective beta-blockers.
A systematic review and meta-analysis of bisoprolol use in COPD patients found that lung function measures, including FEV1 (how much air you can force out in one second) and FVC (total air you can exhale), were not meaningfully worsened by the drug. This is a significant practical advantage, since many people who need a beta-blocker for heart failure or high blood pressure also live with lung disease.
Metabolic Effects
Non-selective beta-blockers are known to interfere with blood sugar regulation and lipid levels, which matters for people with diabetes. In a double-blind, placebo-controlled study of 20 people with type 2 diabetes and high blood pressure, bisoprolol at a standard therapeutic dose did not change blood glucose, long-term blood sugar markers, cholesterol, or triglycerides compared to placebo. No episodes of low blood sugar were observed. This neutral metabolic profile is another practical benefit of its high selectivity.
How Bisoprolol Works Day to Day
Bisoprolol is taken once daily. It has about 80% oral bioavailability, meaning most of the pill reaches your bloodstream. Peak effects on heart rate occur within 1 to 4 hours, and the drug remains active for a full 24 hours at doses of 5 mg or more. Its plasma half-life is 9 to 12 hours, slightly longer in older adults due to natural age-related changes in kidney function.
This long duration of action, combined with its selectivity, is part of why major guidelines favor bisoprolol. The 2024 European Society of Cardiology guidelines recommend beta-blockers as first-line treatment for stable angina. For heart failure with reduced pumping ability, both the American and European guidelines specifically name bisoprolol as one of three beta-blockers proven to reduce mortality and hospitalizations.